title: Dyslipidemias in patients who have chronic kidney disease.
abstract: Patients with CKD are at high risk for developing CVD. In fact, most CKD patients have a 10-year risk of coronary heart disease events greater than or equal to 20%, placing them in the highest risk category according to the National Cholesterol Education Program Adult Treatment Panel III guidelines. For this reason, the National Kidney Foundation K/DOQI guidelines for managing dyslipidemia suggest that CKD patients with LDL greater than or equal to 100 mg/dL (2.59 mmol/L) should be treated with diet and a statin. The K/DOQI guidelines also make it clear that the evidence supporting treatment in CKD populations is lacking however, and that additional placebo-controlled trials are needed. In the mean time, the high incidence of CVD makes intensive monitoring and treatment of dyslipidemias in patients with CKD a reasonable clinical approach.
authors.affiliation: University of Minnesota, Minneapolis, MN 55415, USA. farba002@umn.edu
authors.forename: Kambiz
authors.initials: K
authors.lastname: Farbakhsh
authors.forename: Bertram L
authors.initials: BL
authors.lastname: Kasiske
mesh_terms: D000328:Adult; D002318:Cardiovascular Diseases / Q000150:complications; D003920:Diabetes Mellitus / Q000628:therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology*; D007676:Kidney Failure, Chronic / Q000150:complications*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors